Drugs / GM.CD40L
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00840931 | Feb 2009 → Feb 2014 | leukemia | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02466568 | Jul 2018 → Jul 2019 | lung adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01433172 Comparator | Mar 2012 → Jan 2016 | adenocarcinoma, lung cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM.CD40L | “In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8...” NCT00840931 ↗ |
| Modality | Vaccine | “GM.CD40L bystander vaccination injections” NCT00840931 ↗ |